Best Practice & Research Clinical Endocrinology & Metabolism
Volume 17, Issue 1 , Pages 123-137 , March 2003

Breast cancer and post-menopausal hormone therapy

  • P Kenemans, MD, PhD (Professor and Chairman)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +31-20-4444-813; Fax: +31-20-4444-811.

Received 1 August 2002 ,Accepted 1 September 2002.

References 

  1. Kenemans P, Stampfer M. Hormone replacement therapy and breast cancer. European Journal of Obstetrics, Gynecology,and Reproductive Biology. 1996;67:1–4
  2. Kenemans P, Scheele F, Burger CW. Hormone replacement therapy and breast cancer morbidity, mortality and recurrence. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 1997;71:199–203
  3. Marsden J. Hormone-replacement therapy and breast cancer. Lancet Oncology. 2002;3:303–311 Review
  4. Lacey JV, Devesa SS, Brinton LA. Recent trends in breast cancer incidence and mortality. Environmental and Molecular Mutagenesis. 2002;39:82–88
  5. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncology. 2001;2:133–140
  6. Collaborative group on Hormonal Factors in Breast Cancer . Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347:1713–1727
  7. Collaborative Group on Hormonal Factors in Breast Cancer . Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350:1047–1059
  8. Kenemans P. Menopause, HRT and menopausal symptoms. Journal of Epidemiology and Biostatistics. 1999;4:141–153
  9. Crosignani PG, Kenemans P, Paoletti R, et al.  Hormone replacement and the menopause: a European position paper. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 1997;74:67–72
  10. Grady D, Rubin SM, Petitti DB, et al.  Hormone therapy to prevent disease and prolong life in postmenopausal women. Annals of Internal Medicine. 1992;117:1016–1037
  11. Ettinger B, Friedman GD, Bush T, et al.  Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstetrics and Gynecology. 1996;87:6–12
  12. Sturgeon SR, Schairer C, Brinton LA, et al.  Evidence of a healthy estrogen user survivor effect. Epidemology. 1995;6:227–231
  13. Schairer C, Adami H-O, Hoover R, Persson I. Cause-specific mortality in women receiving hormone replacement therapy. Epidemiology. 1997;8:75–79
  14. Grodstein F, Stampfer M, Colditz GA, et al.  Postmenopausal hormone replacement therapy and mortality. New England Journal of Medicine. 1997;336:1769–1775
  15. Persson I, Yuen J, Bergkvist L. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy—long-term follow-up of a Swedish cohort. International Journal of Cancer. 1996;67:327–332
  16. Hulley S, Furberg C, Barret-Connor E, et al.  Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Journal of the American Medical Association. 2002;288:58–66
  17. Writing Group for the Women's Health Initiative Investigators . Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Journal of the American Medical Association. 2002;288:321–333
  18. Nanda K, Bastian LA, Schulz K. Hormone replacement therapy and the risk of death from breast cancer: a systematic review. American Journal of Obstetrics and Gynecology. 2002;186:325–334
  19. Hesch R-D, Kenemans P. Hormonal prevention of breast cancer: proposal for a change in paradigm. British Journal of Obstetrics and Gynaecology. 1999;106:1006–1018
  20. Kenemans P, Burger CW, Scheele F. Postmenopausal hormone replacement therapy and gynecological malignancies. In:  Paoletti R editors. Women's Health and Menopause, Risk Reduction Strategies—Improved Quality of Health. Hingham, MA: Kluwer Academic Publishers; 1999;p. 225–231
  21. Spicer DV, Pike MC. The prevention of breast cancer through reduced ovarian steroid exposure. Acta Oncologica. 1992;31:167–174
  22. Gompel A, Somai S, Chaouat M, et al.  Hormonal regulation of apoptosis in breast cells and tissues. Steroids. 2000;65:593–598
  23. Ellis PA, Saccani-Jotti G, Clarke R, et al.  Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. International Journal of Cancer. 1997;72:608–613
  24. Liehr JG. Is estradiol a genotoxic mutagenic carcinogen?. Endocrine Reviews. 2000;21:40–54
  25. Richer JK, Jacobsen BM, Manning NG, et al.  Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. Journal of Biological Chemistry. 2002;277:5209–5218
  26. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast proliferation and breast cancer risk. Epidemiologic Reviews. 1993;15:17–35
  27. Pasqualini JR, Paris J, Sitruk-Ware R, et al.  Progestins and breast cancer. Journal of Steroid Biochemistry and Molecular Biology. 1998;65:225–235
  28. Söderqvist G, Olsson H, Wilking N, et al.  Metabolism of estrone sulfate by normal breast tissue: influence of menopausal status and oral contraceptives. Journal of Steroid Biochemistry and Molecular Biology. 1994;48:221–224
  29. Kandouz M, Lombet A, Perrot JY, et al.  Proapoptotic effects of antiestrogens, progestins and androgen in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology. 1999;69:463–471
  30. Sóderqvist G, von Schoultz B, Tani E, Skoog L. Estrogen and progesterone receptor content in breast epithelial cells from healthy women during the menstrual cycle. American Journal of Obstetrics and Gynecology. 1993;168:874–879
  31. Thijssen JH. Oestrogens, progestins and breast proliferation. Zentralblatt für Gynakologie. 1997;119:43–47
  32. Cline JM, Söderqvist G, von Schoultz E, et al.  Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. American Journal of Obstetrics and Gynecology. 1996;174:93–100
  33. Wren BG, Eden JA. Do progestogens reduce the risk of breast cancer? A review of the evidence. Menopause. 1996;3:4–12
  34. Burger CW, Kenemans P. Postmenopausal hormone replacement therapy and cancer of the female genital tract and breast. Current Opinion in Obstetrics and Gynecology. 1998;10:41–45
  35. Verheul HA, Coelingh-Bennink HJ, Kenemans P. Effects of estrogens and hormone replacement therapy on breast cancer risk and on efficacy of breast cancer therapies. Maturitas. 2000;36:1–17
  36. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiologic Reviews. 1993;15:36–47
  37. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. Journal of the National Cancer Institute 2002; 94: 606–616.
  38. Blankenstein MA, van de Ven J, Maitimu-Smeele I, et al.  Intratumoral levels of estrogens in breast cancer. Journal of Steroid Biochemistry and Molecular Biology. 1999;69:293–297
  39. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. New England Journal of Medicine. 1975;293:1167–1170
  40. Ziel HK, Finkle WD, Greenland S. Decline in incidence of endometrial cancer following increase in prescriptions for opposed conjugated estrogens in a prepaid health plan. Gynecologic Oncology. 1998;68:253–255
  41. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. International Journal of Cancer. 1988;42:832–888
  42. Bergkvist L, Adami HO, Persson I, et al.  The risk of breast cancer after estrogen and estrogen–progestin replacement. New England Journal of Medicine. 1989;321:293–297
  43. Colditz GA, Hankinson SE, Hunter DJ, et al.  The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. New England Journal of Medicine. 1995;332:1589–1593
  44. Newcomb PA, Longnecker MP, Storer BE, et al.  Long-term hormone replacement therapy and the risk of breast cancer in postmenopausal women. American Journal of Epidemiology. 1995;142:788–795
  45. Persson I, Thurfjell E, Bergstrom R, Holmberg L. Hormone replacement therapy and the risk of breast cancer. Nested case–control study in a cohort of Swedish women attending mammography screening. International Journal of Cancer. 1997;72:758–761
  46. Persson I, Weiderpass E, Bergkvist L, et al.  Risks of breast and endometrial cancer after estrogen and estrogen–progestin replacement. Cancer Causes Control. 1999;10:253–260
  47. Magnusson C, Baron JA, Correia N, et al.  Breast-cancer risk following long-term oestrogen- and oestrogen–progestin-replacement therapy. International Journal of Cancer. 1999;81:339–344
  48. Schairer C, Lubin J, Troisi R, et al.  Menopausal estrogen and estrogen–progestin replacement therapy and breast cancer risk. Journal of the American Medical Association. 2000;283:485–491
  49. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. Journal of the National Cancer Institute. 2000;92:328–332
  50. Li CI, Weiss NS, Stanford JL, Daling JR. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer. 2000;88:2570–2577
  51. Chen C, Weiss N, Newcomb P, et al.  Hormone replacement therapy in relation to breast cancer. Journal of the American Medical Association. 2002;287:734–741
  52. Newcomb PA, Titus-Ernstoff L, Egan KM, et al.  Postmenopausal estrogen and progestin use in relation to break cancer risk. Cancer Epidemiology, Biomarkers and Prevention. 2002;11:593–600
  53. Ursin G, Tseng C, Paganini-Hill A, et al.  Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer?. Journal of Clinical Oncology. 2002;20:699–706
  54. Sacchini V, Zurrida S, Andreoni G, et al.  Pathologic and biological prognostic factors of breast cancers in short- and long-term hormone replacement therapy users. Annals of Surgical Oncology. 2002;9:266–271
  55. Bonnier P, Sakr R, Bessenay F, et al.  Effets des traitements hormonaux substitutifs de la ménopause sur les facteurs pronostiques des cancers du sein. Gynécologie, Obstétrique and Fertilité. 2000;28:745–753
  56. Fowble B, Hanlon A, Freedman G, et al.  Postmenopausal hormone replacement therapy: effect on diagnosis and outcome in early-stage invasive breast cancer treated with conservative surgery and radiation. Journal of Clinical Oncology. 1999;17:1680–1688
  57. Salmon RJ, Ansquer Y, Asselain B, et al.  Clinical and biological characteristics of breast cancers in post-menopausal women receiving hormone replacement therapy for menopause. Oncology Reports. 1999;6:699–703
  58. Magnusson C, Holmberg L, Norden T, et al.  Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Research and Treatment. 1996;38:325–334
  59. Bonnier P, Bessenay F, Sasco AJ, et al.  Impact of menopausal hormone-replacement therapy on clinical and laboratory characteristics of breast cancer. International Journal of Cancer. 1998;79:278–282
  60. O'Connor IF, Shembekar MV, Shousha S. Breast carcinoma developing in patients on hormone replacement therapy: a histological and immunohistological study. Journal of Clinical Pathology. 1998;51:935–938
  61. Holli K, Isola J, Cuzick J. Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. Journal of Clinical Oncology. 1998;16:3115–3120
  62. Delgado RC, Lubain Lopez DM. Prognosis of breast cancers detected in women receiving hormone replacement therapy. Maturitas. 2001;38:147–156
  63. Jones C, Ingram D, Mattes E, Hahnel R. The effect of hormone replacement therapy on prognostic indices in women with breast cancer. Medical Journal of Australia. 1994;161:106–110
  64. Harding C, Knox WF, Faragher EB, et al.  Hormone replacement therapy and tumour grade in breast cancer: prospective study in screening unit. British Medical Journal. 1996;312:1646–1647
  65. Strickland DM, Gambrell RD, et al.  The relationship between breast cancer survival and prior postmenopausal estrogen use. Obstetrics and Gynecology. 1992;80:400–404
  66. LeBlanc ES, Viscoli CM, Henrich JB. Postmenopausal estrogen replacement therapy is associated with adverse breast cancer prognostic indices. Journal of Women's Health and Gender-based Medicine. 1999;8:815–823
  67. Cobleigh MA, Norlock FE, Oleske DM, Starr A. Hormone replacement therapy and high S phase in breast cancer. Journal of the American Medical Association. 1999;28:1528–1530
  68. Bonnier P, Romain S, Giacalone PL, et al.  Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstetrics and Gynecology. 1995;85:11–17
  69. Manjer J, Malina J, Berglund G, et al.  Increased incidence of small and well-differentiated breast tumours in post-menopausal women following hormone-replacement therapy. International Journal of Cancer. 2001;92:919–922
  70. Bilimoria MM, Winchester DJ, Sener SF, et al.  Estrogen replacement therapy and breast cancer: analysis of age of onset and tumor characteristics. Annals of Surgical Oncology. 1999;6:200–207
  71. Squitieri R, Tartter PI, Ahmed S, et al.  Carcinoma of the breast in postmenopausal hormone user and nonuser control groups. Journal of the American College of Surgeons. 1994;178:167–170
  72. Verkasalo PK, Thomas HV, Appleby PN, et al.  Circulating levels of sex hormones and their relation to risk factors for breast cancer: a cross-sectional study in 1092 pre- and postmenopausal women (UK). Cancer Causes Control. 2001;12:47–59
  73. Pujol P, Galtier-Dereure F, Bringer J. Obesity and breast cancer risk. Human Reproduction. 1997;12:116–125
  74. Longnecker MP, Berlin JA, Orza MJ, Chalmers TC. A meta-analysis of alcohol consumption in relation to risk of breast cancer. Journal of the American Medical Association. 1988;260:652–656
  75. Dorgan JF, Baer DJ, Albert PS, et al.  Serum hormones and the alcohol-breast cancer association in postmenopausal women. Journal of the National Cancer Institute. 2001;93:710–715
  76. Zumoff B. Does postmenopausal estrogen administration increase the risk of breast cancer? Contributions of animal, biochemical and clinical investigative studies to a resolution of the controversy. Proceedings of the Society for Experimental Biology and Medicine. 1998;217:30–37
  77. Kenemans P, Scheele F. Hormone replacement therapy in patients at high risk of developing breast cancer: the use of a combined risk model. Gynecological Endocrinology. 1997;11:17–22
  78. Scheele F, Burger CW, Kenemans P. Postmenopausal hormone replacement in the woman with a reproductive risk factor for breast cancer. Maturitas. 1999;33:191–196
  79. Ford D, Easton DF. The genetics of breast and ovarian cancer. British Journal of Cancer. 1995;72:805–812
  80. Fishman J, Osborne MP, Telang NT. The role of estrogen in mammary carcinogenesis. Annals of the New York Academy of Sciences. 1995;768:91–100
  81. Early Breast Cancer Trialist's Collaborative Group . Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet. 1996;348:1189–1196
  82. Col NF, Hirota LK, Orr RK, et al.  Hormone replacement therapy after breast cancer; a systematic review and quantitative assessment of risk. Journal of Clinical Oncology. 2001;19:2357–2363
  83. O'Meara ES, Rossing MA, Daling JR, et al.  Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. Journal of the National Cancer Institute. 2001;93:754–762
  84. Pritchard KI. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer and a review of possible alternatives. Annals of Oncology. 2001;12:301–310
  85. Pritchard KJ. Hormone replacement in women with a history of breast cancer. Oncologist. 2001;6:353–362
  86. Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. Journal of Steroid Biochemistry and Molecular Biology. 2001;76:231–238
  87. Barrett-Connor E. Raloxifene: risks and benefits. Annals of the New York Academy of Sciences. 2001;949:295–303
  88. Delmas PD, Bjarnason NH, Mitlak BH, et al.  Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. New England Journal of Medicine. 1997;337:1641–1647
  89. Berning B, Bennink HJ & Fauser BC. Tibolone and its effect on bone: a review. Climacteric 2001; 4: 120–136.
  90. Gompel A, Chaouat M, Jacob D et al. In vitro studies of tibolone in breast cells. Fertility and Sterility 2002; 78: 351–359.
  91. Cauley JA, Norton L, Lippman ME. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Research and Treatment 2001; 65: 125–134.
  92. Barrett-Connor E, Grady D & Sashegyl A. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. Journal of the American Medical Association 2002; 287: 847–857.
  93. Albertazzi P, Purdie DW. The nature and utility of the phytoestrogens; a review of the evidence. Maturitas. 2002;42:173–185
  94. Loprinzi CL, Michalak JC, Quella SK, et al.  Megestrol acetate for the prevention hot flushes. New England Journal of Medicine. 1994;331:347–352
  95. Freedman RR. Physiology of hot flashes. American Journal of Human Biology. 2001;13:453–464
  96. Loprinzi CL, Sloan JA, Perez EA, et al.  Phase III evaluation of fluxetine for treatment of hot flashes. Journal of Clinical Oncology. 2002;20:1578–1583
  97. Nilsson K, Heimer G. Low-dose oestradiol in the treatment of urogenital oestrogen deficiency—a pharmacodynamic study. Maturitas. 1992;13:121–127

PII: S1521-690X(02)00084-2

doi: 10.1016/S1521-690X(02)00084-2

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 17, Issue 1 , Pages 123-137 , March 2003

Article Tools

* Image Usage & Resolution